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Abstract: Hyperglycemia frequently occurs with acute medical illness, especially among 
patients with cardiovascular disease, and has been linked to increased morbidity and mortality 
in critically ill patients. Even patients who are normoglycemic can develop hyperglycemia in 
response to acute metabolic stress. An expanding body of literature describes the benefits of 
normalizing hyperglycemia with insulin therapy in hospitalized patients. As a result, both the 
American Diabetes Association and the American College of Endocrinology have developed 
guidelines for optimal control of hyperglycemia, specifically targeting critically ill, hospital-
ized patients. Conventional blood glucose values of 140–180 mg/dL are considered desirable 
and safely achievable in most patients. More aggressive control to ,110 mg/dL remains con-
troversial, but has shown benefits in certain patients, such as those in surgical intensive care. 
  Intravenous infusion is often used for initial insulin administration, which can then be transitioned 
to subcutaneous insulin therapy in those patients who require continued insulin maintenance. 
This article reviews the data establishing the link between hyperglycemia and its risks of morbid-
ity and mortality, and describes strategies that have proven effective in   maintaining glycemic 
control in high-risk hospitalized patients.
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Introduction
Diabetes is a chronic disease that causes elevated blood glucose concentrations and 
disturbances of carbohydrate and lipid metabolism as a result of compromised pancre-
atic production of insulin or insulin resistance.1 In 2007, diabetes affected 23.6 million 
people in the US, with an estimated annual cost of $174 billion, and type 2 diabetes 
mellitus accounts for 90%–95% of all diagnosed cases in adults.2 Approximately one-
quarter of affected individuals (5.7 million in the US) are undiagnosed, placing them 
at risk for complications, such as blindness, kidney failure, neuropathy, myocardial 
infarction, and stroke.2 According to data from the 1999–2000 National Health and 
Nutrition Examination Survey, even among patients diagnosed with diabetes, only 
37% were treated to the glycosylated hemoglobin (HbA1c) concentration of ,7.0% 
recommended by the American Diabetes Association.3
Hyperglycemia is a frequent but underappreciated problem seen in many critically 
ill patients. For critically ill inpatients, hyperglycemia is considered to require treat-
ment when blood glucose level is persistently $180 mg/dL (.10.0 mmol/L).4 While 
hyperglycemia during a critical illness is understood to pose a danger for patients with 
known diabetes, those most at risk of hyperglycemia are actually patients not previ-
ously known to have diabetes, in one study accounting for 12% of all adults admitted Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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to hospital.5 In this trial, such individuals suffered greater 
mortality and a lengthier hospital stay than their known 
diabetic counterparts.5
The glucose status of hospitalized patients was once 
considered less important than the management of their 
presenting illness.6,7 This changed with the recognition 
that overall outcomes among hospitalized patients may 
be negatively affected by uncontrolled hyperglycemia or 
diabetes.   Particularly important is that aggressive treatment 
of hyperglycemia with insulin can minimize morbidity and 
mortality, a benefit that can extend up to years beyond the 
immediate illness.5,8 Since the first publication of recom-
mendations for management of inpatient hyperglycemia 
and diabetes in 2004,7,9 aggressive diagnosis and treatment 
of hyperglycemia among critically ill patients has become 
a priority. Standardized protocols typically use a sequenced 
combination of intravenous and subcutaneous short-, 
  intermediate-, or long-acting insulin formulations.8,10,11 The 
evidence   suggests, however, that not all patients exhibit 
benefits from an   intensive insulin therapy regimen (eg, with 
target blood glucose ,110 mg/dL)12,13 as opposed to a 
conventional glucose target of 140–180 mg/dL,4 with the 
clearest benefits to date demonstrated for surgical intensive 
care unit (ICU) patients.14 These findings suggest the need 
for further research to define optimal glycemic targets and 
hyperglycemia management protocols differentially in spe-
cific subpopulations of seriously ill patients.
Hyperglycemia and illness
Hyperglycemia in the hospital setting may occur from stress, 
decompensation of type 1 or 2 diabetes, or other diabetes, and 
either withholding various antihyperglycemic medications or 
administration of hyperglycemia-inducing agents.15 Three 
types of hospitalized patients with hyperglycemia are typically 
reported in the research literature: those with a medical his-
tory of diabetes (eg, fasting blood glucose $126 mg/dL, two-
hour oral glucose tolerance test blood glucose $200 mg/dL, 
or HbA1c $6.5%)15 which the patient’s clinician has diag-
nosed previously; unrecognized diabetes, ie, hyperglycemia 
(fasting blood glucose $126 mg/dL or random blood glu-
cose $200 mg/dL) occurring during hospitalization but not 
recognized as frank diabetes by the hospital clinician, with 
diabetes diagnosis later confirmed after hospitalization by 
standard criteria; and stress- or hospital-related hyperglyce-
mia, ie, hyperglycemia (fasting blood glucose $126 mg/dL 
or random blood glucose $200 mg/dL) occurring during 
hospitalization in previously normoglycemic patients and 
blood glucose level returning to normal during recovery.4,15 
The HbA1c level can be used to distinguish patients with 
previously unrecognized diabetes (HbA1c $6.5%) from 
those who are normoglycemic but experiencing temporary, 
stress hyperglycemia (HbA1c ,6.5%).4 In suspected cases 
of stress hyperglycemia, it is important to conduct follow-
up blood glucose testing in order to confirm a persistent 
return to normoglycemia postdischarge. While some have 
argued that stress hyperglycemia signals underlying glucose 
dysregulation or prediabetes, several reports fail to support 
this notion, showing that few such patients go on to develop 
frank diabetes.16,17
Not all patients who display hyperglycemia require glu-
cose-lowering therapy. To warrant treatment, hyperglycemia 
must reach certain thresholds and persist over time.4 Based 
on current consensus guidelines, general inpatient hypergly-
cemia may warrant insulin therapy only when blood glucose 
values reach a threshold of $140 mg/dL (7.8 mmol/L);4 in 
critically ill patients, the treatment threshold has been set at 
180 mg/dL (10.0 mmol/L).4
Hyperglycemia has been reported in the settings of 
trauma, stroke, myocardial infarction, and sepsis.18 In a 
study of 100 patients admitted to a medical ICU (including 
51 patients with normal glucose homeostasis at baseline), 
some degree of hyperglycemia was seen in all but four of 
these patients.18 The prevalence of hyperglycemia occurring 
during a serious illness is especially apparent among patients 
with cardiovascular disease. In the Euro Heart Survey, 31% 
of 4961 adults referred to a cardiologist for treatment of 
coronary artery disease were found to have diabetes.19 Among 
923 patients without known diabetes presenting with acute 
coronary artery disease, 36% had impaired glucose tolerance 
and 22% had newly diagnosed diabetes. Similarly, a retro-
spective analysis of nondiabetic patients admitted to hospital 
for acute myocardial infarction revealed a high prevalence 
of hyperglycemia (at discharge, 35% had impaired glucose 
tolerance and 31% had unrecognized diabetes), which was 
associated with a substantially increased risk of inhospital 
morbidity and mortality.20 Patients with higher admission 
glucose levels were more likely to experience subsequent 
reinfarction, rehospitalization for congestive heart failure, 
a major cardiovascular event, or death.20 As shown in 
  Figure 1, a similar relationship between elevated blood 
glucose and poor outcomes, including hospital mortality, 
has been observed in the broader ICU population.21 These 
investigations have shown that glucose levels are an inde-
pendent predictor of poor short- and long-term outcomes, 
including mortality, and they suggest that glucose-lowering 
interventions may improve such outcomes.20Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Unfortunately, many critically ill patients are still not 
evaluated for hyperglycemia or unrecognized diabetes on 
admission to hospital, and hyperglycemia is not routinely 
managed aggressively. Levetan et al22 screened 1034 con-
secutive hospitalized adult patients without a prior history 
of diabetes for glucose values .200 mg/dL, and found that 
37.5% of medical patients and 33% of surgical patients had 
hyperglycemia, although documentation of abnormal glyce-
mia was found in just one-third of their hospital records, and 
only three discharge reports suggested a possible diagnosis 
of diabetes. Furthermore, the investigators, on following up 
the hospitalized patients postdischarge, found that what was 
perceived in the hospital as stress hyperglycemia associated 
with hospitalization may in fact have been frank diabetes; 
glucose elevations were sustained in a number of these 
patients over several months of follow-up after hospital 
discharge.22,23
Mortality, diabetes, 
and hyperglycemia 
in cardiovascular patients
Type 2 diabetes mellitus is a well documented risk factor 
for cardiovascular mortality and predicts poor outcome after 
myocardial infarction.19 As shown in the Norfolk cohort of 
the European Prospective Investigation of Cancer study, even 
a moderately elevated HbA1c concentration, although within 
the normal range, indicated an increased risk of cardiovascular 
disease and mortality.24 Critically ill patients with new-onset 
hyperglycemia, in addition, appear to have significantly higher 
inhospital mortality and worse functional outcomes than 
those with previously diagnosed diabetes or normoglycemia 
(Figure 2), with even modest elevations in mean glucose level 
contributing to increased risk for inhospital death.5
The relationship between glucose level and mortality post-
myocardial infarction was first recognized in the mid 1970s. 
In 1988, Malmberg and Rydén25 documented a statistically 
significant increase in post-myocardial infarction mortality 
among patients with diabetes compared with those without 
diabetes both during the acute hospital stay (25% versus 16%; 
P , 0.02) and over the year following the event (53% versus 
28%; P , 0.001). The authors also noted a greater tendency 
of fatal reinfarction in the diabetic group (30% versus 14%; 
P , 0.05). These data have been substantiated and expanded 
upon by results from several other trials, demonstrating 
that hyperglycemia with or without established diabetes 
increased mortality risk after acute myocardial infarction or 
other forms of cardiovascular disease (including coronary 
artery disease, coronary artery bypass grafting surgery,   
or stroke).20,26–30 Thus, it appears that hyperglycemia, 
rather than diabetes status per se, influences morbidity and   
mortality risk.
However, results from another study of high-risk patients 
with diabetes and cardiovascular disease undergoing 
percutaneous coronary intervention found no significant 
difference in cardiovascular outcomes (including death) 
in patients with preoperative HbA1c levels of #7.0% 
or .7.0%.31 These findings may support the notion that 
a history of hyperglycemia imposes a long-term risk of 
adverse cardiovascular events even after HbA1c is managed 
back to normal levels.
0
10
20
30
40
50
80–99 120–
139
140–
159
160–
179
180–
199
200–
249
250–
299
≥300
Mean ICU glucose, mg/dL
M
o
r
t
a
l
i
t
y
,
 
%
100–
119
Figure 1 iCU mean glucose value and hospital mortality.21 Glucose values shown as a range of mean values; Chi-square test used for trend (P < 0.001) analysis.
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Temporal patterns in glucose excursions may be pre-
dictive of adverse cardiac events. In one study, persistent 
increases in fasting glucose over the course of hospitaliza-
tion for acute myocardial infarction was more predictive of 
increased mortality than admission fasting glucose alone, 
regardless of diabetic status at admission (Figure 3).32 
Results from this study also showed that while outcomes 
improved in patients whose increased fasting glucose at 
admission was normalized at discharge, they remained 
at increased risk of long-term mortality compared with 
patients with persistently normal fasting glucose levels 
(Figure 3).32
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Figure 3 The effect of changes in fasting glucose levels on the Global Registry of Acute Coronary Events Score-adjusted hazard ratio for mortality. Copyright © 2009, 
The American Journal of Cardiology. Used with permission from Aronson D, Hammerman H, Suleiman M, Markiewicz w. Usefulness of changes in fasting glucose during 
hospitalization to predict long-term mortality in patients with acute myocardial infarction. Am J Cardiol. 2009;104(8):1013–1017.32
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Controlling glucose  
in cardiovascular disease
Patients in the Leuven studies who had undergone cardiac 
surgery were subsequently evaluated in a subgroup analysis, 
with long-term follow-up of high-risk cardiac patients. The 
investigators assessed outcomes in this population four years 
after the original admission and reported that the benefit 
of intensive insulin therapy in the prolonged-stay patients 
($three days in ICU) was sustained, ie, only 23.1% of inten-
sive treatment patients had died at four years compared with 
36.2% of patients in the conventional insulin therapy group 
(P = 0.03). The authors concluded that tighter short-term 
glycemic control during intensive care yielded long-term 
survival benefits in a cardiovascular population.33
The Diabetes and Insulin-Glucose Infusion in Acute 
Myocardial Infarction (DIGAMI) study established that 
survival rates among post-myocardial infarction patients with 
diabetes could be improved if they were treated to normo-
glycemia with insulin therapy.34 In this study, 620 patients 
who had experienced a myocardial infarction in the previous 
24 hours and had a blood glucose level .198.2 mg/dL (with 
or without documented diabetes) received either an insulin-
glucose infusion followed by subcutaneous insulin dosing 
four times daily for three months or longer or conventional 
insulin therapy (standard care, with insulin given when 
indicated). At one year, patients who received aggressive 
treatment experienced an approximately 30% relative reduc-
tion in mortality compared with conventional insulin therapy 
(P = 0.027). The advantage was even greater among subjects 
with a low cardiovascular risk profile and no prior insulin 
therapy (52% reduction in mortality; P = 0.046).34 This ben-
efit was sustained at 3.5 years’ follow-up, when an absolute 
reduction in mortality of 11% was observed.35 A follow-up 
trial, DIGAMI 2, failed to replicate these results,36 likely 
because the intensive treatment group did not achieve signifi-
cantly improved glucose control compared with conventional 
insulin therapy.37 However, DIGAMI 2 did show the admis-
sion blood glucose level to be a strong independent predictor 
of mortality following acute myocardial infarction.36
Furnary et al29 evaluated the benefit of tight glycemic 
control among patients with diabetes undergoing coro-
nary artery bypass grafting. Continuous insulin infusion 
via the Portland Protocol was used to maintain blood 
glucose levels between 100 and 150 mg/dL in the periop-
erative period; this was compared with historical controls 
given subcutaneous insulin treatment to sustain glucose 
levels ,200 mg/dL. Of 3554 patients studied, mortality was 
significantly lower in those treated with continuous insulin 
infusion (P , 0.0001). Recent work from this group sug-
gested that three   postoperative days of excellent glycemic 
control (blood glucose ,150 mg/dL) decreased the risk of 
deep sternal wound infection by 77%, mortality by 60%, and 
length of stay, thus apparently eliminating the incrementally 
increased risk of complications previously seen in patients 
with diabetes.38
Recently, results of the Action to Control Cardiovascular 
Risk in Diabetes (ACCORD),39 the Veterans Affairs Dia-
betes Trial (VADT),40 and Action in Diabetes and Vascular 
Disease: Preterax and Diamicron MR Controlled Evalua-
tion (ADVANCE)41 trials have been published, indicating 
that intensive glycemic control (to target HbA1c ,6.0% 
or #6.5%, respectively) in patients with type 2 diabetes 
mellitus at high cardiovascular risk failed to reduce major 
cardiovascular events and, in fact, was associated with 
higher mortality in the ACCORD study. The exact reason for 
the increase in mortality is not clear, but a similar median 
HbA1c concentration was achieved in the ADVANCE study 
with no increased mortality.42 An additional analysis of 
the ACCORD data suggests that an HbA1c concentration 
of ,7.0% alone cannot account for the increased mortal-
ity risk nor is it a predictor of mortality risk.43 While these 
studies leave many questions unanswered, it is important 
to note that patients in each study arm were treated with 
a variety of glucose-lowering drugs rather than defined 
regimens; thus, these studies were not specifically testing 
the effects of insulin therapy. In fact, only 40% of subjects 
in the intensive control arm of ADVANCE were prescribed 
insulin.41 In their appraisal of these three trials, the American 
Diabetes Association and the American Heart Association 
did not suggest major changes in glycemic control targets 
but rather emphasized individualized care.42 A recent ret-
rospective cohort analysis of almost 28,000 patients with 
type 2 diabetes mellitus from the UK General Practice 
Research Database showed the lowest and highest achieved 
HbA1c concentrations (median HbA1c 6.4% and 10.5%, 
respectively) were associated with an increased risk of 
all-cause mortality for patients whether they were treated 
with oral therapy or insulin (1.52, 95% confidence interval 
[CI]: 1.32–1.76], P , 0.0001; 1.79 [95% CI: 1.56–2.06], 
P , 0.0001, respectively).44 The authors posit that this 
increase in mortality in the lowest HbA1c group might have 
been associated with hypoglycemia because mortality was 
higher in patients who had severe hypoglycemia compared 
with those without severe hypoglycemia. These study results 
also support recommendations for an HbA1c target value that 
differs depending on the individual patient.45Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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One ongoing trial is evaluating the impact of insulin 
therapy on cardiovascular outcomes in patients with cardio-
vascular disease who are not hospitalized. In the Outcome 
Reduction with Initial Glargine Intervention (ORIGIN) 
trial, investigators aim to determine whether maintaining 
normoglycemia (fasting glucose ,95 mg/dL) with insulin 
glargine can reduce the risk of cardiovascular morbidity 
and/or mortality among outpatients with impaired fasting 
glucose, impaired glucose tolerance, or early type 2 diabetes 
mellitus who are at high risk for vascular disease.46 The goal 
of the Impact of Tight Glycemic Control in Acute Myocar-
dial Infarction trial is to assess whether aggressive insulin 
therapy can improve myocardial function and perfusion and 
alter vascular risk factors in patients with acute myocardial 
infarction and hyperglycemia.47
Controlling glucose in critical  
and intensive care patients
Several landmark studies have shown that insulin therapy to 
achieve tight glucose control improves acute and long-term 
outcomes in critically ill adults. In the first Leuven study, 
van den Berghe et al8 studied 1548 surgical ICU patients 
randomized to intensive insulin therapy (to achieve blood 
glucose levels of 80–110 mg/dL) or conventional therapy 
(insulin at blood glucose levels .215 mg/dL to reach 
180–200 mg/dL). At 12 months, a 42% reduction in ICU 
mortality was observed, and overall inhospital mortality 
decreased by 34% with intensive insulin therapy (P , 0.01). 
The benefit was especially apparent in patients who remained 
in the ICU for more than five days (10.6% versus 20.2% 
with intensive versus conventional treatment, respectively; 
P = 0.005). Intensive therapy also reduced morbidity, includ-
ing the number of episodes of septicemia, acute renal failure, 
red blood cell transfusions, and critical illness neuropathy 
(Figure 4).8
A later Leuven study of 1200 adult medical ICU patients 
(767 of whom stayed in the ICU for at least a third day) fol-
lowed the same protocol for intensive versus conventional 
insulin treatment.13 Morbidity was significantly reduced 
among patients on intensive therapy (P = 0.04) and, although 
overall mortality did not differ between groups, inhospital 
mortality was significantly reduced among patients under 
ICU care for three days or more (52.5% versus 43% for 
conventional versus intensive insulin therapy, respectively; 
P = 0.009).13 However, results also indicated more frequent 
hypoglycemia in the intensive treatment group (3.1% versus 
18.7% for conventional versus intensive insulin therapy; 
P , 0.001). Thus, benefits of tight glycemic control were 
again shown to be greatest among patients who had more 
severe illness and required a longer ICU stay. Increased 
risk of hypoglycemia may be an expected consequence of 
such studies, although there was no evidence of clinically 
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significant harm as a result. However, two intensive insulin 
therapy trials, ie, the European Glucontrol trial and the 
Volume Substitution and Insulin Therapy in Severe Sepsis 
(VISEP) trial, were halted because of such safety concerns. 
The Glucontrol trial evaluated the role of intensive insulin 
therapy (4.4–6.1 mmol/L) or “intermediate glucose control” 
insulin therapy (7.8–10.0 mmol/L) in medical ICU patients.48 
The trial was halted because of a near fourfold increase in 
hypoglycemia associated with intensive insulin therapy, with 
no significant survival benefit compared with intermediate 
glucose control. In the VISEP trial, ICU patients with severe 
sepsis were randomized to intensive or conventional insulin 
therapy.49 At 28 days, there was a statistically significant, 
nearly fourfold increase in the rate of severe hypoglycemia 
(defined as 2.2 mmol/L [#40 mg/dL]) that was considered 
to be life-threatening.49,50 In another study, Arabi et al51 found 
that there was no statistically significant increase in mortality 
in ICU patients with hypoglycemia except in patients with 
severe hypoglycemia (#1.2 mmol/L) and in patients with an 
admission blood glucose level of #10 mmol/L.
The large Normoglycemia in Intensive Care Evaluation-
Survival Using Glucose Algorithm Regulation (NICE-
SUGAR) trial treated patients (n = 6104) who were expected 
to be in the ICU for at least three days with either intensive 
glycemic control (defined as a blood glucose target of 
81–108 mg/dL) or conventional glycemic control (target of 
144–180 mg/dL) using intravenous insulin.12 There was a 
significant difference between the intensive and conventional 
treatment arms for death at 90 days (27.5% versus 24.9%; 
odds ratio: 1.14 [95% CI: 1.02–1.28], respectively; P = 0.02), 
and a significant increase in severe hypoglycemia (,40 mg/
dL) was reported in the intensive group compared with the 
conventional group (6.8% versus 0.5%; P , 0.001). The lack 
of benefits in the NICE-SUGAR study may not be because 
of reduced glucose levels, which were modest (145 versus 
118 mg/dL on average), but may stem from the use of insulin 
with a high relative rate of hypoglycemia and other factors 
specific to the NICE-SUGAR treatment regimens. A large 
meta-analysis of 26 trials involving over 13,567 patients, and 
which included the NICE-SUGAR data, was conducted to 
clarify the influence of intensive insulin therapy compared 
with conventional insulin therapy on mortality and severe 
hypoglycemia in ICU.14 Results showed that intensive insulin 
therapy in the ICU setting had no effect on overall risk of 
90-day mortality. There was a sixfold increased risk of severe 
hypoglycemia among patients given intensive insulin therapy 
compared with the control treatment regardless of the type of 
ICU or the intensity of insulin therapy (Figure 5).8,12–14,49,52–73 
However, further analysis revealed significant   heterogeneity 
among the included trials, based on type of ICU unit and 
target glucose levels. When these variables were included in 
the analysis model, it was found that surgical ICU patients 
(versus medical ICU) given intensive insulin therapy showed 
a significantly lower relative risk of 90-day mortality (relative 
risk: 0.63, 95% CI: 0.44–0.91; P = 0.02). This meta-analysis 
highlights the inconsistent outcomes observed in critically ill 
patients given intensive insulin therapy. The variability in the 
literature is likely due to key methodologic differences among 
the available trials, including widely different criteria for 
“usual” glycemic control (.10 mmol/L to 6.0–8.0 mmol/L) 
versus “intensive” control (4.0–8.3 mmol/L).14 Further 
research is required to define optimal glycemic targets and 
insulin regimens better, and appropriate selection criteria for 
managing hyperglycemia in subgroups of ICU patients.
Intensive insulin therapy in special populations has been 
shown to improve key clinical outcomes. A study of 700 
critically ill patients admitted to the pediatric ICU found that 
intensive insulin therapy resulted in a statistically significant 
reduction in blood glucose levels, duration of pediatric ICU 
stay, and the inflammatory marker, C-reactive protein, but 
significantly more hypoglycemic events compared with 
conventional insulin therapy. There were significantly fewer 
deaths in the intensive insulin therapy group and, after cor-
rection for baseline factors, hypoglycemia (defined as either 
blood glucose #2.2 mmol/L or ,1.7 mmol/L [#39.6 mg/dL 
or ,30.6 mg/dL]) was not an independent predictor of 
mortality.74
Patients with traumatic brain injuries or acute stroke are 
at increased risk of stress-related hyperglycemia. In a study 
of 240 patients with traumatic brain injury, intensive insulin 
therapy reduced infection rates, shortened the patient’s stay 
in ICU and improved neurologic outcomes compared with 
conventional insulin therapy. Hypoglycemic events occurred 
in only seven patients. However, there was no significant dif-
ference in mortality between the two groups at six months 
follow-up.75 With acute stroke, approximately 40% of patients 
will exhibit hyperglycemia for several days following the 
event.76 In a small sample of acute ischemic stroke patients, 
higher mean blood glucose levels monitored continuously 
over 72 hours post-stroke (7 mmol/L) were correlated 
with larger infarct size and poorer functional outcomes.77 
In one meta-analysis (n = 32 trials), short-term mortality 
was threefold higher, and poorer functional outcome was 
seen among nondiabetic patients with moderately elevated 
glucose levels (.6.1 mmol/L) following ischemic stroke.78 
To date, there is no clear evidence of a clinical benefit of Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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No. Deaths/Total No. Patients
Study IIT Control Risk ratio (95% CI)
Mixed ICU
Yu et al52 4/28 4/27 0.96 (0.27–3.47)
Henderson et al53 5/32 7/35 0.78 (0.28–2.22)
Mitchell et al54 9/35 3/35 3.00 (0.89–10.16)
Wang et al55 7/58 26/58 0.27 (0.13–0.57)
Azevedo et al56 38/168 42/169 0.91 (0.62–1.34)
McMullin et al57 6/11 4/9 1.23 (0.49–3.04)
Devos et al58 107/550 89/551 1.20 (0.93–1.55)
Brunkhorst et al49 98/247 102/288 1.12 (0.90–1.39)
Iapichino et al59 15/45 12/45 1.25 (0.66–2.36)
He et al60 16/58 29/64 0.61 (0.37–1.00)
Zhang et al61 4/168 6/170 0.67 (0.19–2.35)
De La Rosa Gdel et al62  102/254 96/250 1.05 (0.84–1.30)
Arabi et al63 72/266 83/257 0.84 (0.64–1.09)
Mackenzie et al64 39/121 47/119 0.82 (0.58–1.15)
NICE-SUGAR12 829/3010 751/3012 1.10 (1.01–1.20)
All mixed ICU patients 1351/5051 1301/5089 0.99 (0.87–1.12)
Medical ICU
Bland et al65 1/5 2/5 0.50 (0.06–3.91)
Van den Berghe et al13  214/595 228/605 0.95 (0.82–1.11)
Walters et al66 1/13 0/12 2.79 (0.12–62.48)
Farah et al67 22/41 22/48 1.17 (0.77–1.78)
Oksanen et al68 13/39 18/51 0.94 (0.53–1.68)
Bruno et al69 2/31 0/15 2.50 (0.13–49.05)
All medical ICU patients 253/724 270/736 1.00 (0.78–1.28)
Surgical ICU
Van den Berghe et al8 55/765 85/783 0.66 (0.48–0.92)
Grey et al70 4/34 6/27 0.53 (0.17–1.69)
Bilotta et al71 6/40 7/38 0.81 (0.30–2.20)
He et al72 7/150 6/38 0.30 (0.11–0.83)
Bilotta et al73 5/48 6/49 0.85 (0.28–2.60)
All surgical ICU patients 77/1037 110/935 0.63 (0.44–0.91)
All ICU patients 1681/6812 1681/6760 0.93 (0.83–1.04)
Favors IIT Favors control
0.1 11 0
Risk ratio (95% CI)
Figure 5 Effect of intensive insulin therapy versus conventional insulin therapy on mortality in intensive care unit patients. Tests for heterogeneity: mixed iCU: Q statistic, 
29.54 (P , 0.01), I2, 52.6%; medical iCU: Q statistic, 2.05 (P = 0.84), I2, 0.0%; surgical iCU: Q statistic, 2.78 (P = 0.60), I2 statistic, 0.0%; all iCU patients: Q statistic, 46.67 
(P , 0.01), I2, 46.4%. Copyright © 2009, Access Copyright Used with permission from Griesdale DE, de Souza RJ, van Dam RM, et al. intensive insulin therapy and mortality 
among critically ill patients: A meta-analysis including NiCE-SUGAR study data. CMAJ. 2009;180(8):821–827.14
Abbreviations: Ci, confidence interval; NICE-SUGAR, Normoglycemia in Intensive Care Evaluation–Survival Using Glucose Algorithm Regulation; ITT, intensive insulin 
therapy.
insulin therapy during acute stroke treatment. In the largest 
trial to date (Glucose Insulin in Stroke Trial, n = 933), stroke 
patients admitted with hyperglycemia and randomized 
to receive 24 hours of continuous glucose potassium and 
insulin showed an all-cause mortality rate and functional 
outcomes similar to patients who were randomized to receive   
placebo.79
There are many variables that factor into the risks and 
benefits of intensive insulin therapy in the hospital setting. 
These include differences in patient population, disease 
severity, different protocols, different glycemic targets, dif-
ferent definitions of hypoglycemia, and different underlying 
comorbidities. While each of these can directly impact the 
results of a randomized clinical trial, their clinical sig-
nificance remains to be fully elucidated. Another possibly 
important factor that may impact patient outcome with insulin 
therapy is blood glucose variability, which has gained atten-
tion in recent years after observations of heightened risk of 
hypoglycemia with intensive insulin therapy. The evidence 
indicates that wide fluctuation in blood glucose concentra-
tions increases risk of mortality and other poor outcomes 
in critically ill patients.80–84 In one of the earliest of these 
studies,81 researchers derived standard deviation values as a 
marker of glucose variability from large databases of blood 
glucose measurements in critically ill patients (n = 7049). 
Analysis showed significantly higher blood glucose stan-
dard deviation values among nonsurvivors compared with 
survivors. Logistic regression revealed a positive and inde-
pendent predictive relationship between glucose variability 
and risk of mortality that was stronger than that observed 
between mortality and mean glucose concentration.81 
More recently, Dossett et al83 and Al-Dorzi et al84 observed 
similar predictive relationships between glucose variability 
and mortality in surgical ICU patients. In the study from 
Al-Dorzi et al,84 daytime glucose fluctuation (the difference 
between the highest and lowest glucose values) was similar 
among patients (n = 523) who were randomized to either 
intensive or conventional insulin therapy. Regardless of Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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insulin therapy group, those patients with wide glycemic 
fluctuation (versus narrow fluctuation) exhibited a higher 
likelihood of mortality (22.2% versus 8.4%; P , 0.001), 
even when controlling for patient age, diabetic status, and 
daily insulin dose.84 Further research is needed to determine 
whether reducing glycemic fluctuation improves patient   
outcomes.
Guidelines for insulin therapy  
in critically ill hospitalized patients
The American Diabetes Association has issued guidelines 
for managing diabetes in critically ill patients in the hos-
pital   setting.15 The recommendations for blood glucose 
levels for critically ill patients target an initial glucose 
level of #180 mg/dL (10.0 mmol/L), with intravenous 
infusion of insulin being the preferred route of adminis-
tration.15 After initiation of intravenous insulin, glucose 
level should be maintained between 140 and 180 mg/dL 
(7.8 and 10.0 mmol/L). Glycemic targets of ,110 mg/dL 
(6.1 mmol/L) are not recommended.15 Complete descrip-
tions of recommended insulin infusion methods are avail-
able in American Diabetes Association guidelines and other 
sources.37,85–89
Successful protocols for intravenous insulin administra-
tion all share a number of features, including established 
efficacy with minimal hypoglycemia risk, adaptability to 
all hospital units, and ease of implementation. Algorithms 
designed and standardized to the needs of a multidisciplinary 
team, including physicians, nurses, pharmacists, and cardi-
ologists, and implemented by nursing staff, are becoming 
more common, because they ensure consistency of care 
with cost-conscious appeal.85,87,90–95 In addition, strategies 
for addressing hypoglycemia episodes should be a standard 
component of infusion protocols, preferably set up in advance 
and implemented by a well-trained multidisciplinary team. 
Many hypoglycemia episodes can be forestalled by coordi-
nating nutrition (eg, tube feeding, total parenteral nutrition) 
and insulin therapy.85,86
As the condition of critically ill patients improves, 
they are transitioned into the general hospital population. 
Observational studies suggest that, like critically ill patients, 
hyperglycemia in the general hospital inpatient is associ-
ated with poorer outcomes, including increased mortality 
(versus normoglycemic patients).5 There are currently no 
prospective investigations of illness or functional outcomes, 
however, with glycemic management in noncritically ill 
inpatients with hyperglycemia. Moreover, in the general hos-
pital   setting, highly skilled nursing staff specially trained to 
implement intravenous insulin therapy regimens and invasive 
  monitoring techniques are not available. Nevertheless, based 
on the available data, the American Diabetes Association 
  recommends the active management of hyperglycemia in 
the non-ICU setting. The joint American Diabetes Associa-
tion and American Association of Clinical Endocrinologists 
guidelines recommend glycemic management in ICU patients 
transitioning to general inpatient care, as well as noncriti-
cally ill patients who exhibit premeal blood glucose levels 
of .140 mg/dL (7.8 mmol/L).15 For most inpatients, routine 
bedside blood glucose monitoring performed prior to meals 
and at bedtime can identify patients with hyperglycemia.4 In 
the general inpatient setting, scheduled subcutaneous insu-
lin is the preferred method for achieving desired glycemic 
targets. Such a regimen should include basal, nutritional, 
and supplemental (eg, corrective) components.15 Successful 
implementation of a subcutaneous insulin regimen to achieve 
recommended glycemic targets safely in the non-ICU gen-
eral hospital setting is possible given proper staff training 
and systems coordination so that prandial insulin doses are 
adjusted appropriately in accord with meal delivery timing, 
content, and patient consumption.4 Appropriately selected 
ICU patients will need to transition to subcutaneous insulin 
administration.4,15 Although there are no data identifying the 
best protocol for transitioning to subcutaneous insulin, the 
American Diabetes Association and American Association 
of Clinical Endocrinologists suggest that 75%–80% of the 
total daily intravenous infusion dose be divided into basal 
and prandial components. The use of basal insulin is widely 
recommended to expedite the transition to subcutaneous 
insulin therapy from intravenous insulin therapy and to 
maintain glucose control;4 a long-acting analog, such as 
insulin glargine or insulin detemir, may be the best option.86 
The long-acting formulations can address basal needs while 
minimizing the risk of hypoglycemia, which is a significant 
challenge with shorter-acting analogs.96,97 To prevent hyper-
glycemia, subcutaneous insulin must be initiated 1–4 hours 
prior to discontinuation of the intravenous insulin.15
Effective hospital discharge
Transitioning care from the inpatient to the outpatient setting 
is important to achieve better glycemic control and improve 
outcomes.98 For the patient with newly diagnosed diabetes, 
effective discharge includes providing the necessary patient 
education and skills training and a clear postdischarge plan 
that is well documented and easily accessible to the patient’s 
outpatient clinicians.98 In addition, patients should have a 
basic understanding of the disease and insulin   administration, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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be able to perform glucose self-monitoring, and be aware of 
the risks of hypoglycemia.99 These   individuals should receive 
clear written instructions, which will be a useful at-home 
guide and reference for both outpatients and their caregivers. 
More comprehensive diabetes self-care education should 
be arranged in the community outpatient setting. It is also 
critical for hospital staff to communicate with outpatient 
care providers, either directly or via a hospital discharge 
summary, particularly with regard to a care plan, complica-
tions, and comorbidities.15 Patients with diabetes should be 
instructed to see their primary care clinician within seven to 
30 days of discharge. For normoglycemic individuals who 
experienced stress hyperglycemia during their illness, it will 
be critical to determine whether hyperglycemia resolves 
and remains at normal levels postdischarge. These patients 
should see their clinicians one month postdischarge.99 While 
no formal recommendations have been published regarding 
postdischarge follow-up for such patients, it seems reason-
able to suggest that they self-monitor blood glucose levels at 
home in the interim period between discharge and follow-up 
with their physician. If the patient detects hyperglycemia 
during this period, they should contact their care provider.
Summary
Hyperglycemia and large variability in glycemic indices 
increases the risk of morbidity and mortality substantially 
among critically ill patients and those with cardiovascular 
disease. A significant body of evidence supports the use of 
insulin therapy for glucose control in appropriately selected 
critically ill patients. It is now recommended that all patients 
receive glucose testing on admission to the hospital and 
glucose-lowering therapy if hyperglycemia is found. Many 
organizations, including the American Diabetes Association 
and the American Association of Clinical Endocrinologists, 
endorse glycemic control for hospitalized patients and sup-
port the use of proven insulin infusion protocols and hypogly-
cemia prevention measures to achieve normoglycemia safely 
in this population. While conventional glucose-lowering 
interventions that aim to maintain blood glucose levels 
between 140–180 mg/dL are recommended for critically ill 
patients,4 intensive glucose-lowering protocols having target 
glucose levels set at ,110 mg/dL remain controversial. 
Benefits with such protocols, in terms of increased survival 
and shorter ICU stays, have been shown in surgical ICU 
patients14 and those who remained in the ICU for three days 
or longer;13 benefits have not been observed in other patient 
groups and more frequent hypoglycemia has been reported. 
Given these inconsistent findings, further investigation of 
aggressive glucose-lowering therapy in specific patient 
populations is required.
Inpatient management is only the first phase in a new 
paradigm of glycemic control. Persistent hyperglycemia 
or postdischarge diabetes must be identified to allow for 
blood glucose control after hospital discharge; this should 
be an integral part of the comprehensive treatment plan for 
cardiovascular patients. Finally, providing patients with the 
tools and knowledge to maintain long-term normoglycemia 
after discharge via a self-management education program 
based on a safe and effective combination of insulin analog 
and oral antidiabetic drugs can improve the prognosis for 
those at continued cardiovascular risk due to uncontrolled 
hyperglycemia.
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